Leukemia and rosiglitazone

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

and Rosiglitazone

The antidiabetic thiazolidinediones, which include troglitazone and rosiglitazone, are ligands for the nuclear receptor peroxisome proliferatora c t i v a t e d receptor (PPA R )and exert their antihyperglycemic e ffects by regulation of PPA R–responsive genes. We report here that PPA Ractivation by troglitazone depends on the experimental setting. Troglitazone acts as a partial agonist for PPA...

متن کامل

Rosiglitazone and cardiovascular risk.

In this issue of the Journal, Nissen and Wolski1 report the results of a meta-analysis of treatment trials of rosiglitazone, as compared either with other therapies for type 2 diabetes or with placebo. Eligible studies included randomized trials that lasted for at least 24 weeks. The prespecified primary end points of interest were myocardial infarction and death from cardiovascular causes. The...

متن کامل

Rosiglitazone (Avandia) and macular edema.

The condition: Macular edema occurs when the blood vessels leak plasma into the surrounding retina. Among people with type 2 diabetes, it can be found in 15% of those who use insulin and 4% of those who do not. Risk factors for macular edema and its symptoms are listed in Box 1. Cases of rosiglitazone-related macular edema were first described in September 2005. The manufacturer of the drug, Gl...

متن کامل

Rosiglitazone and Risk of Cancer

OBJECTIVE Despite experimental data suggesting a protective effect of peroxisome proliferator-activated receptor-gamma agonists with respect to malignancies, results of available epidemiological studies on the incidence of cancer in rosiglitazone-treated patients are not univocal. The aim of this meta-analysis of randomized clinical trials is to assess the effect of rosiglitazone on the inciden...

متن کامل

Rosiglitazone: An Update

Background The Food and Drug Administration (FDA) is currently considering the fate of rosiglitazone, a thiazolidinedione (TZD) first linked to an increase in cardiovascular events in 2007. The May/June 2007 edition of the RxPress (http://pmpr.pharm.uic.edu/dig/rx/2007%20 v8n3%20MayJun.pdf) summarizes the initial paper, a meta-analysis by Nissen and colleagues, as well as preliminary data (an u...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Saudi Pharmaceutical Journal

سال: 2016

ISSN: 1319-0164

DOI: 10.1016/j.jsps.2015.03.017